Dr. Beck rejoined Innovimmune as VP of Business Development & Strategic Alliances in 2016, a role he previously held from 2012-2014. Prior to rejoining Innovimmune, Dr. Beck served as VP of BD at Exicure Inc. and had previously spent 16 years at Roche, most recently as Executive Director Global Business Development, managing the team responsible for licensing activities in Drug Delivery, RNA therapeutics and Process Research. During his tenure they executed >45 transactions including licensing deals with Tekmira, Aegis and the $125M acquisition of Mirus Bio. From 2004-2008 Dr. Beck served as Global Alliance Director managing comercial alliances with Trimeris and Aspreva, led scientific due diligences and was a key member of the deal teams for the HCV collaborations with Pharmasset ($168M) and Intermune ($470M). He also led the divestment of Roche's RNA therapeutics business and the Tamiflu licensing team in support of the Pandemic Preparedness Taskforce. Dr. Beck serves on the New York University Venture Fund Biotech Review Board, is a Pharmacist by training and has a Ph.D. in Cell Biology, both from Aston University, U.K.